# Investigation of *cis*- and *trans*-4-fluoroprolines as enantioselective catalysts in a variety of organic transformations

Daryl Q. J. Yap, Raju Cheerlavancha, Renecia Lowe, Siyao Wang and Luke Hunter\*

\*Email: l.hunter@unsw.edu.au

### SUPPLEMENTARY MATERIAL

### **Contents:**

Synthetic procedures	S-2
HPLC traces	S-8
NMR spectra	S-16
References	S-29

### Synthetic procedures

Cis-4-fluoroproline hydrochloride (2)



A solution of ester **27** (0.101 g, 0.410 mmol) in 2M aq. HCl (2.0 mL) was refluxed overnight. The solution was cooled, diluted with ethanol, decolourised with activated charcoal, and filtered through Celite<sup>®</sup>. The filtrate was concentrated *in vacuo* to give the title compound as a white solid (59.9 mg, 86%); m.p. 154–156 °C; <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O)  $\delta$  5.51 (ddd, *J* = 2.8, 5.6, 51.8 Hz, 1H, FCH), 4.67–4.62 (m, 1H, C(O)CH), 3.90–3.79 (ddd, *J* = 2.1, 13.9, 19.0 Hz, 1H, NC<u>H</u>H), 3.67–3.49 (ddd, *J* = 3.4, 13.9, 37.1 Hz, 1H, NCH<u>H</u>), 2.76–2.55 (m, 2H, CF–C<u>H<sub>2</sub>–CH); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$ –175.0 (m, 1F); <sup>1</sup>H NMR data in accordance with literature values.<sup>[1]</sup></u>

#### Trans-4-fluoroproline hydrochloride (3)



A solution of ester **29** (0.198 g, 0.802 mmol) in 2M HCl (3.5 mL) was refluxed overnight, then cooled, diluted with ethanol, decolourised with activated charcoal, and filtered through Celite<sup>®</sup>. The filtrate was then concentrated *in vacuo* to give the title compound as a white solid (0.152 g, >99%); m.p. 104–106 °C; <sup>1</sup>H NMR (300 MHz, MeOD)  $\delta$  5.42 (d, *J* = 51.6 Hz, 1H, FCH), 4.63 (m, 1H, C(O)CH), 3.84–3.49 (m, 2H, NCH<sub>2</sub>), 2.79–2.60 (m, 2H, CF–C<u>H<sub>2</sub></u>–CH); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –175.8 (m, 1F); <sup>1</sup>H NMR data in accordance with literature values.<sup>[1]</sup>

2-Methyl-2-(3-oxobutyl)cyclohexane-1,3-dione (14)



Acetic acid (0.10 mL), hydroquinone (45.5 mg) and freshly distilled methyl vinyl ketone (1.3 mL, 16 mmol) were added to a well-stirred suspension of 2-methyl-1,3-cyclohexanedione (1.01 g, 7.99 mmol) and distilled water (12 mL). The mixture was stirred at 75 °C for 1 h, then cooled to room temperature. NaCl (4.00 g) was added, followed by ethyl acetate (20 mL). The aqueous layer was extracted with ethyl acetate ( $2 \times 10$  mL), and the combined organic extracts were washed with brine ( $2 \times 10$  mL), dried (MgSO<sub>4</sub>) and concentrated *in vacuo* to give crude ketone **14** as a yellow oil (0.950 g, 61%). In some cases the crude product was further purified by flash chromatography (95:1 hexane / ethyl acetate). Data for **14**: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  2.77–2.57 (m, 4H), 2.33 (t, *J* = 7.2 Hz, 2H), 2.13 (s, 3H), 2.10 (t, J = 7.2Hz, 2H), 1.89–1.87 (m, 2H), 1.23 (s, 3H); <sup>1</sup>H NMR data in accordance with literature values.<sup>[6]</sup>

### **Benzoylacetonitrile (24)**



A mixture of ethyl benzoate (10 mL, 70 mmol), freshly prepared sodium methoxide (12.7 g, 234 mmol) and acetonitrile (90 mL) was refluxed for 3 h. After cooling to room temperature, the formed white precipitate was filtered, redissolved in 3 M HCl (200 mL) and the mixture was extracted with DCM (2 × 300 mL). The combined organic layer was then washed with brine (100 mL), dried (MgSO<sub>4</sub>) and concentrated *in vacuo*. Purification by flash chromatography (3:1 *n*-hexane/ethyl acetate) provided nitrile **28** as a white solid (5.78 g, 57%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.91–7.90 (m, 2H, ArH), 7.65 (m, 1H, ArH), 7.53–7.49 (m, 2H, ArH), 4.11 (s, 2H, CH<sub>2</sub>); <sup>1</sup>H NMR data in accordance with literature values.<sup>[7]</sup>

#### *N*-Boc-*trans*-4-hydroxyproline (26)



*Trans*-4-hydroxyproline (5.02 g, 38.3 mmol) was dissolved in 2:1 THF/H<sub>2</sub>O (50 mL), after which 2M NaOH solution (21 mL) and Boc<sub>2</sub>O (10.0 g, 46.0 mmol) were added. The resulting solution was stirred overnight, then concentrated *in vacuo*. The residue was dissolved in ethyl acetate, and sat. aq. KHSO<sub>4</sub> was added to adjust to pH = 2. The solution was extracted with ethyl acetate ( $3 \times 70$  mL), and the combined organic extracts were washed with water (50 mL) and brine (50 mL) then dried (MgSO<sub>4</sub>). The solvent was removed *in vacuo* to give the title compound as a pale yellow syrup (8.11 g, 92%); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.49–4.32 (m, 2H, C<u>H</u>OH and C(O)CH), 3.63–3.45 (m, 2H, NCH<sub>2</sub>), 2.39–2.06 (m, 2H, COH–C<u>H<sub>2</sub></u>–CH), 1.43 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), rotamers; <sup>1</sup>H NMR data in accordance with literature values.<sup>[2]</sup>

### N-Boc-cis-4-fluoroproline methyl ester (27)



Iodomethane (2.5 mL, 40 mmol) was added to a mixture of acid **26** (7.56 g, 32.7 mmol), DMF (120 mL) and K<sub>2</sub>CO<sub>3</sub> (22.4 g) at 0 °C, and the mixture was stirred overnight. The solution was then quenched with water (120 mL), extracted with ethyl acetate (5 × 50 mL) and washed with water (25 mL) and brine (25 mL). The organic layer was dried (MgSO<sub>4</sub>), and concentrated *in vacuo* to give *N*-Boc-*trans*-4-hydroxyproline methyl ester as a yellow syrup (5.73 g, 71%); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.48–4.36 (m, 2H, CHOH and C(O)CH), 3.73 (s, 3H, OCH<sub>3</sub>), 3.66–3.42 (m, 2H, NCH<sub>2</sub>), 2.34–2.02 (m, 2H, COH–CH<sub>2</sub>–CH), 1.43 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), rotamers; <sup>1</sup>H NMR data in accordance with literature values.<sup>[3]</sup>

A solution of *N*-Boc-*trans*-4-hydroxyproline methyl ester (3.18 g, 13.0 mmol) in dry DCM (200 mL) was cooled to -78 °C. DeoxoFluor<sup>TM</sup> (3.7 mL, 20.1 mmol) was added, and the mixture was stirred overnight while gradually warming to room temperature. The solution was then quenched with sat. NaHCO<sub>3</sub>, and the organic portion was then washed with water (150 mL), dried (MgSO<sub>4</sub>) and concentrated *in vacuo*. Purification by flash chromatography (3:1 *n*-hexane/ethyl acetate) provided the title compound as a yellow syrup (2.36 g, 74%); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  5.18 (d, *J* = 53.2 Hz, 1H, FCH), 4.47 (dd, *J* = 9.5, 35.2 Hz, 1H, OC-CH), 3.89–3.48 (m, 5H, OCH<sub>3</sub> and NCH<sub>2</sub>), 2.53–2.20 (m, 2H, CF–CH<sub>2</sub>–CH), 1.44 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –173.1 (m, 1F), rotamers; <sup>1</sup>H NMR data in accordance with literature values.<sup>[4]</sup>

#### N-Boc-cis-4-hydroxyproline (28)



Pyridine (0.23 mL, 2.8 mmol) was added to a solution of acid **26** (0.328 g, 1.42 mmol) in anhydrous DCM (10 mL) at 0 °C. Mesyl choride (0.22 mL, 2.8 mmol) was added, and the mixture was stirred overnight at 0 °C. The reaction was then quenched with water (10 mL) and the aqueous layer was extracted with DCM ( $3 \times 20$  mL). The combined organic layers were washed with water (10 mL) and brine (10 mL), then dried (MgSO<sub>4</sub>) and concentrated *in vacuo* without heating to give an intermediate mesylate compound as an orange-brown syrup (0.342 g, 78%). This compound was used directly in the subsequent step without purification or characterisation.

Diisopropylethylamine (7.9 mL, 45 mmol) was added to a solution of the intermediate mesylate compound (14.0 g, 45.1 mmol) in dioxane (200 mL). The mixture was heated at 95 °C for 2 h, then cooled and concentrated *in vacuo*. The residue was dissolved in DCM (150 mL) and washed

with water (50 mL) and brine (50 mL), then dried (MgSO<sub>4</sub>) and concentrated *in vacuo* to yield an intermediate lactone compound as a dark brown syrup (7.50 g, 78%); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  5.26 (br, 1H, OCH), 4.41–4.22 (m, 1H, NCH), 3.89–3.34 (m, 2H, NCH<sub>2</sub>), 2.66–1.89 (m, 2H, CH–C<u>H<sub>2</sub></u>–CH), 1.41–1.13 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), rotamers; <sup>1</sup>H NMR data in accordance with literature values.<sup>[5]</sup>

LiOH (5.35 g, 223 mmol) was added to a solution of the intermediate lactone compound (15.9 g, 74.4 mmol) in MeOH:THF:water (2:2:3, 400 mL), and the mixture was stirred overnight. The solvent was removed *in vacuo*, and ethyl acetate (200 mL) was added. The pH was adjusted to 2 by addition of sat. aq. KHSO<sub>4</sub>. The solution was then saturated by addition of NaCl, and the aqueous layer was extracted with ethyl acetate ( $3 \times 100$  mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), then dried (MgSO<sub>4</sub>) and concentrated *in vacuo* to give the title compound as a dark brown syrup (16.3 g, 95%); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.50–4.33 (m, 2H, CHOH and C(O)CH), 3.88–3.50 (m, 2H, NCH<sub>2</sub>), 2.74–2.21 (m, 2H, COH–CH<sub>2</sub>–CH), 1.45 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), rotamers; <sup>1</sup>H NMR data in accordance with literature values.<sup>[2]</sup>

#### N-Boc-trans-4-fluoroproline methyl ester (29)



Iodomethane (40 µL, 0.64 mmol) was added to a mixture of acid **28** (96.2 mg, 0.416 mmol), DMF (10 mL) and K<sub>2</sub>CO<sub>3</sub> (1.00 g) at 0 °C. The mixture was stirred overnight at 0 °C. The mixture was then quenched with water (5 mL) and extracted with ethyl acetate ( $3 \times 20$  mL). The combined organic layers were washed with water (10 mL) and brine (10 mL), then dried (MgSO<sub>4</sub>) and concentrated *in vacuo* to give *N*-Boc-*cis*-4-hydroxyproline methyl ester as a yellow syrup (75.7 mg, 74%); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  4.49–4.31 (m, 2H, CHOH and C(O)CH), 3.73 (s, 3H, OCH<sub>3</sub>), 3.68–3.42 (m, 2H, NCH<sub>2</sub>), 2.34–2.02 (m, 2H, COH–CH<sub>2</sub>–CH), 1.43 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>), rotamers; <sup>1</sup>H NMR data in accordance with literature values.<sup>[3]</sup>

A solution of *N*-Boc-*cis*-4-hydroxyproline methyl ester (0.737 g, 3.00 mmol) in dry DCM (60 mL) was cooled to -78 °C. DeoxoFluor<sup>TM</sup> (0.83 mL, 4.5 mmol) was added, and the mixture was stirred overnight while gradually warming to room temperature. The solution was then quenched with sat. NaHCO<sub>3</sub>, and the layers were separated. The organic phase was washed with water (20 mL), dried (MgSO<sub>4</sub>) and concentrated *in vacuo*. Purification by flash chromatography (4:1 *n*-hexane/ethyl acetate) provided the title compound as a pale yellow syrup (0.252 g, 34%); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  5.18 (d, *J* = 53.2 Hz, 1H, FCH), 4.46 (dd, *J* = 9.4, 34.8 Hz, 1H, C(O)CH), 3.88–3.47 (m, 5H, OCH<sub>3</sub> and NCH<sub>2</sub>), 2.52–2.19 (m, 2H, CF–CH<sub>2</sub>–CH), 1.43 (s, 9H, C(CH<sub>3</sub>)<sub>3</sub>); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  –173.0 (m, 1F), rotamers; <sup>1</sup>H NMR data in accordance with literature values.<sup>[4]</sup>

### Determining the optical purity of ketone 21: formation of diastereoisomeric acetals (30)



A mixture of ketone **21** (7.8 mg, 0.055 mmol), (2R,3R)-2,3-butanediol (10 µl, 0.11 mmol) and *p*-toluenesulfonic acid (5 mol%) in dry benzene (3.0 mL) was refluxed for 1 h, then cooled to room temperature, extracted with ethyl acetate (20 mL) and washed with sat. aq. NaHCO<sub>3</sub> (3 × 15 mL). The organic layer was dried (MgSO<sub>4</sub>) and concentrated *in vacuo* to provide the crude acetal as a yellow oil (11.6 mg). The diastereoisomeric ratio was determined by <sup>13</sup>C{<sup>1</sup>H} NMR analysis (100 MHz, CDCl<sub>3</sub>), observing signals at  $\delta$  43.0 / 42.6, 38.4 / 38.1, 37.0 / 36.7 and 28.8 / 28.4.

# **HPLC Traces**



### $\beta$ -Hydroxyketone **11** (obtained using L-proline **1** as catalyst)

 $\beta$ -Hydroxyketone 11 (obtained using DL-proline as catalyst)



β-Hydroxyketone 11 (obtained using *cis*-4-fluoroproline 2 as catalyst)



β-Hydroxyketone 11 (obtained using *trans*-4-fluoroproline **3** as catalyst)



Robinson product **15** (obtained using L-proline **1** as catalyst)



Robinson product **15** (obtained using DL-proline as catalyst)







Robinson product 15 (obtained using *trans*-4-fluoroproline 3 as catalyst)



Mannich product 18 (obtained using L-proline 1 as catalyst)





Mannich product 18 (obtained using DL-proline as catalyst)







Mannich product 18 (obtained using trans-4-fluoroproline 3 as catalyst)



Pyran 25 (obtained using L-proline 1 as catalyst)



Pyran **25** (obtained using DL-proline as catalyst)



Pyran 25 (obtained using *cis*-4-fluoroproline 2 as catalyst)



Pyran 25 (obtained using *trans*-4-fluoroproline 3 as catalyst)



# NMR Spectra

# <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) of acid **2**



# <sup>19</sup>F NMR (282 MHz, D<sub>2</sub>O) of acid **2**



### <sup>1</sup>H NMR (300 MHz, MeOD) of acid 3



# <sup>19</sup>F NMR (282 MHz, MeOD) of acid **3**



# <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of β-hydroxyketone 11



# <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) of Robinson triketone intermediate 14



# <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of Robinson product 14



# <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) of Michael product **21**



<sup>13</sup>C {<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>) of acetals **30** (obtained using L-proline **1** as catalyst)



# <sup>13</sup>C {<sup>1</sup>H} NMR (76 MHz, CDCl<sub>3</sub>) of acetals **30** (obtained using DL-proline as catalyst)



 $^{13}C$  {<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>) of acetals **30** (obtained using *cis*-4-fluoroproline **2** as <u>catalyst</u>)



 $\frac{1^{3}C \{^{1}H\}}{C \{^{1}H\}}$  NMR (101 MHz, CDCl<sub>3</sub>) of acetals **30** (obtained using *trans*-4-fluoroproline **3** as <u>catalyst</u>)



# <sup>1</sup>H NMR (400 MHz, DMSO) of pyran **25**



### References

- [1] M. Hudlický, J. Fluorine Chem. 1993, 60, 193.
- [2] S. Yang, J. He, Chem. Commun. 2012, 48, 10349.
- [3] F. Z. Liu, H. Fang, H. W. Zhu, Q. Wang, Y. Yang, W. F. Xu, *Bioorg. Med. Chem.* 2008, 16, 578.
- [4] J. Chiba, G. Takayama, T. Takashi, M. Yokoyama, A. Nakayama, J. J. Baldwin, E. McDonald, K. J. Moriarty, C. R. Sarko, K. W. Saionz, R. Swanson, Z. Hussain, A. Wong, N. Machinaga, *Bioorg. Med. Chem.* 2006, 14, 2725.
- [5] J. Seo, P. Martasek, L. J. Roman, R. B. Silverman, *Bioorg. Med. Chem.* 2007, 15, 1928.
- [6] R. Pedrosa, J. M. Andrés, R. Manzano, C. Pérez-López, *Tetrahedron Lett.* 2013, 54, 3101.
- [7] M. S. Gowda, S. S. Pande, R. A. Ramakrishna, K. R. Prabhu, *Org. Biomol. Chem.* 2011, 9, 5365.